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Extracts from the Ginkgo biloba tree are widely used as herbal medicines, and include bilobalide (BB) and
ginkgolides A and B (GA and GB). Here we examine their effects on human 5-HT3A and 5-HT3AB
receptors, and compare these to the effects of the structurally related compounds picrotin (PTN) and
picrotoxinin (PXN), the two components of picrotoxin (PTX), a known channel blocker of 5-HT3, nACh
and GABAA receptors. The compounds inhibited 5-HT-induced responses of 5-HT3 receptors expressed in
Xenopus oocytes, with IC50 values of 470 mM (BB), 730 mM (GB), 470 mM (PTN), 11 mM (PXN) and >1 mM
(GA) in 5-HT3A receptors, and 3.1 mM (BB), 3.9 mM (GB), 2.7 mM (PTN), 62 mM (PXN) and >1 mM (GA) in
5-HT3AB receptors. Radioligand binding on receptors expressed in HEK 293 cells showed none of the
compounds displaced the speciﬁc 5-HT3 receptor antagonist [3H]granisetron, conﬁrming that they do not
act at the agonist binding site. Inhibition by GB at 5-HT3A receptors is weakly use-dependent, and
recovery is activity dependent, indicating channel block. To further probe their site of action at 5-HT3A
receptors, BB and GB were applied alone or in combination with PXN, and the results ﬁtted to a math-
ematical model; the data revealed partially overlapping sites of action. We conclude that BB and GB block
the channel of the 5-HT3A receptor. Thus these compounds have comparable, although less potent,
behaviour than at some other Cys-loop receptors, demonstrating their actions are conserved across the
family.
 2010 Published by Elsevier Ltd.1. Introduction
Flavonoids and terpene lactones are the two major types of
active ingredients extracted from the leaves, roots and bark of the
Ginkgo biloba tree (Chen et al., 2007; van Beek, 2005). The clinically
relevant leaf extract EGb761 is enriched in these compounds and
contains, among others, the terpene lactones bilobalide (BB) and
ginkolides A and B (GA, GB). Picrotoxin (PTX), a GABA receptor
antagonist, is also plant derived (from the fruit of Anamirta coccu-
lus), and contains two components that are structurally related to
theseG. biloba constituents (Fig.1A; picrotoxinin (PXN) and picrotin
(PTN)). Like PTX, BB and the ginkgolides are inhibitors of ionotropic
GABA and glycine receptors, and all of these compounds bind
in the receptor channel (Fig. 1B; Heads et al., 2008; Erkkila et al.,, g-aminobutyric acid; 5-HT,
, ginkgolide B; BB, bilobalide;
: þ44 1223 333345.
Elsevier Ltd.2008; Huang et al., 2004; Hawthorne et al., 2006; Kondratskaya
et al., 2005).
GABA and glycine receptors, like 5-HT3 and nACh receptors, are
members of the Cys-loop family of neurotransmitter-gated
receptors. These proteins play a major role in fast synaptic trans-
mission in both the central and peripheral nervous systems. They
consist of ﬁve symmetrically arranged subunits, each of which
contains a large extracellular N-terminal domain, four trans-
membrane a-helices (M1eM4), of which M2 lines the central ion-
conducting pore, and a large intracellular loop between M3 and
M4 which is responsible for channel conductance and intracellular
modulation (Thompson and Lummis, 2006a,b). GABA and glycine
receptors are chloride-selective, and activation generally results in
a hyperpolarising current that is inhibitory. Classic inhibitors of
these receptors such as bicuculline, picrotoxin and strychnine
cause uncontrolled muscle contractions and/or convulsions
(Jarboe et al., 1968). As the ginkgolides are also antagonists of
these receptors, it is surprising that they are not also convulsants,
but instead may have anti-convulsant, neuro-protective, anxiolytic
and other beneﬁcial properties (Ahlemeyer and Krieglstein, 2003;
Kiewert et al., 2007; Sasaki et al., 1997). Given the sequence
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Fig. 1. Structures of the compounds used in this study (Panel A), and an alignment of human Cys-loop receptor M2 regions (Panel B). The alignment includes the human 5-HT3
receptor A and B subunits in addition to subunits from other Cys-loop receptors that are inhibited by BB, GB and PTX. M2 residues are usually referred to using prime (0) notation,
which is shown below the alignment. Accession numbers for the alignment are: 5-HT3A (P46098), 5-HT3B (O95264), glycine a1 (P23415), glycine b2 (P48167), GABAA a1 (P14867),
GABAA b1 (P18505), GABAA g2 (Q8N1C3).
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and the fact that PTX blocks 5-HT3 receptor responses, it is
possible that the ginkgolides also bind to the 5-HT3 receptor,
which might provide some explanation for these different
properties.
In this study we compare the inhibitory effects of BB, GA, GB,
PTN and PXN on 5-HT3A and 5-HT3AB receptors. Using two-elec-
trode voltage-clamp of Xenopus oocytes and competition radio-
ligand binding on transfected HEK 293 cells we provide the ﬁrst
account of BB and GB inhibition of 5-HT3 receptors, and probe their
mechanisms of action at the 5-HT3A receptor.2. Materials and methods
2.1. Materials
PXN and PTN were separated and puriﬁed by recrystallisation following short
column vacuum chromatography from PTX purchased from SigmaeAldrich Pty.
Ltd (NSW, Australia). BB, GA and GB were isolated from a 50:1 G. biloba leaf
extract purchased from Winshing Pty Ltd (NSW, Australia) and puriﬁed by short
column chromatography and recrystallisation. The 1H and 13C NMR spectra of the
puriﬁed compounds were consistent with the published data (Perry et al., 2001;
van Beek, 2005), and indicated purity> 98% in all cases. Human 5-HT3A (acces-
sion number: P46098) and 5-HT3B (O95264, both kindly donated by John Peters),
and mouse 5-HT3A (Q6J1J7) and 5-HT3B (Q9JHJ5, kindly donated by Ewan Kirk-
ness) were used.2.2. Receptor expression
Human 5-HT3A and 5-HT3B subunit cDNAs were cloned into pGEMHE for oocyte
expression (Liman et al., 1992) and pcDNA3.1 (Invitrogen, Paisley, U.K.) for expres-
sion in HEK 293 cells. cRNA was in vitro transcribed from linearised pGEMHE cDNA
template using the mMessage mMachine T7 Transcription kit (Ambion, Austin,
Texas, USA). Stage V and VI oocytes were injected with 50 nl of ∼300 ng ml1 cRNA,
and currents were recorded 1e4 days post-injection. A ratio of 1:3 (A:B) was used for
the expression of heteromeric 5-HT3 receptors.2.3. Oocyte maintenance
Xenopus laevis oocyte positive females were purchased from NASCO (Fort
Atkinson, Wisconsin, USA) and maintained according to standard methods. Har-
vested stage V-VI Xenopus oocytes were washed in four changes of ND96 (96 mM
NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.5), de-folliculated in 1.5 mgml1
collagenase Type 1A for approximately 2 h, washed again in four changes of ND96
and oocytes stored in ND96 containing 2.5 mM sodium pyruvate, 50 mM genta-
mycin, 0.7 mM theophylline.2.4. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were maintained on 90 mm tissue
culture plates at 37 C and 7% CO2 in a humidiﬁed atmosphere. They were cultured in
DMEM:F12 with GlutaMAX I media (Dulbecco’s Modiﬁed Eagle’s Medium /Nutrient
Mix F12 (1:1), Invitrogen, Paisley, UK) containing 10% foetal calf serum. For radioligand
binding studies, cells in 90 mm dishes were transfected using polyethyleneimine
(PEI): 30 ml PEI (1 mg /ml), 5 ml cDNA and 1 ml DMEM were incubated for 10 min at
room temperature, added drop wise to a 80e90% conﬂuent plate, and incubated for
3e4 days before use.2.5. Electrophysiology
Using two electrode voltage clamp, Xenopus oocytes were clamped at 60 mV
using an OC-725 ampliﬁer (Warner Instruments, Connecticut, USA), Digidata 1322A
and the Strathclyde Electrophysiology Software Package (Department of Physiology
and Pharmacology, University of Strathclyde, UK). Currents were ﬁltered at
a frequency of 1 kHz. Micro-electrodes were fabricated from borosilicate glass
(GC120TF-10, Harvard Apparatus, Edenbridge, Kent, UK) using a two stage hori-
zontal pull (P-87, Sutter Instrument Company, California, USA) and ﬁlled with 3 M
KCl. Pipette resistances ranged from 0.5e1.5 MU. Oocytes were perfused with saline
at a rate of 15 mlmin1. Drug application was via a simple gravity fed system cali-
brated to run at the same rate. Extracellular saline contained (mM), 96 NaCl, 2 KCl, 1
MgCl2 and 5 mM HEPES; adjusted to pH 7.4 with NaOH.
Analysis and curve ﬁtting was performed using Prism V3.02 (GraphPad Soft-
ware, San Diego, California, USA, www.graphpad.com). Concentration-response data
for each oocyte was normalised to the maximum current for that oocyte. For inhi-
bition curves, antagonists were routinely co-applied in the presence of agonist. For
PXN, oocytes were also pre-treated with the compound for 20 s. A 2 min wash was
used between drug applications. The mean and S.E.M. for a series of oocytes was
Table 1
Parameters obtained from concentrationeresponse curves.
Receptor pEC50 (M) EC50 (mM) Hill slope n
5-HT3A 5.76 0.03 1.73 2.56 0.31 6
5-HT3AB 4.55 0.05 28.1 1.00 0.12 8
Values are mean SEM.
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Prism v3.02) to the following Hill equation:
IA ¼ Imin þ
Imax  Imin
1þ 10nHðlogA50log AÞ (1)
where A is the concentration of ligand present; IA is the current in the presence of
ligand concentration A; Imin is the current when A¼ 0; Imax is the current when
A¼N , A50 is the concentration of Awhich evokes a current equal to (Imaxþ Imin)/2;
and nH is the Hill coefﬁcient. Results are presented as mean S.E.M.. Statistical
analysis was performed using ANOVA in conjunctionwith a Dunnett’s post-hoc test.
In order to evaluate whether different channel blocking compounds shared
a binding site (scenario 1) or bound at discrete sites (scenario 2) the effect of co-
application of the compounds was compared with a predicted outcome for each
scenario given the observed effects of the two compounds individually
using equations from Kenakin (1997) and analysed using SPSS16.0 (SPSS Inc., Ilinoi,
USA). 97)
Scenario 1: Where compounds share a binding site it was assumed that the
extent of binding would be determined by a competitive interaction between
the compounds such that the proportion of binding sites occupied (Pocc) in the
presence of two competing compounds is given by the following expression:
Pocc ¼ AKA þ BKB1þ AKA þ BKB
(2)
where A and B are the concentrations of two ligands and KA and KB are their afﬁnity
constants respectively.
If it is assumed that receptor occupancy is directly proportional to receptor
blockade, it follows that where A alone causes a functional inhibition of IA (and
likewise for B), then the inhibition observed in the presence of A and B (IAB1), where
the two compounds compete for the same site, is given by the following expression:
IAB1 ¼
IA þ IB  ð2IAIBÞ
1 ðIAIBÞ
(3)
Scenario 2: Where the two compounds bind in discrete locations and therefore
do not interfere with each other’s binding, the proportion of receptors occupied
by one or both compound, and therefore the inhibition observed in the presence
of A and B (IAB2), will be given by the following expression:
IAB2 ¼ IA þ IB  IAIB (4)
In each individual experiment, for each combinationof inhibitors, datavalueswere
obtained for IA, IB and IAB. From IA and IB predicted values of IAB1 and IAB2 were also
derived. A two-way ANOVAwas performed on values of IAB, IAB1 and IAB2 in which the
distinction between IAB, IAB1 and IAB2 was treated as a ﬁxed factor and the variation in
levels of inhibition between experiments was treated as a random factor. Where the
ANOVA indicateda signiﬁcantdifference (P< 0.05) between IAB, IAB1 and IAB2 a post-hoc
analysis was carried out using the WallereDuncan method to identify homogenous
subsets with a signiﬁcance level of 0.05 and a Type I /Type II error ratio if 100.
Our models were based on the following assumptions: 1. that the channel
blocking compounds only effect the response that is seenwhen the channel is open.
Hence, in the absence of the agonist 5-HT, the channel blockers have no effect; 2. the
binding of the compounds do not affect the agonist action of 5-HT at the orthosteric
binding site; 3. that once the compounds have bound they completely block
conductance through the channel; 4. that where the binding sites of two compounds
overlap, only one or other is able to bind at any one time and that the compounds
effectively compete for that binding site according to the usual Gaddum competitive
model (Gaddum, 1937; Colquhoun, 2006); 5. where the binding sites of two
compounds do not overlap, that both compounds are capable of binding indepen-
dently to their respective sites; 6. binding of the compounds is in equilibrium. In the
case of condition 5 it is possible that the binding of one compound may prevent
access of another to its own site. However, in practice this will not inﬂuence the
analysis since the functional consequence of the binding of both compounds
compared to one will be the same, namely complete channel blockade. Different
sub-IC50 concentrations of each of the compounds (BB 16 mM, GB 11 mM and PXN
5 mM) were chosen to allow distinction between the different scenarios.
2.6. Radioligand binding
Competition binding (8 point) was performed on at least three separate plates of
transfected cells. Brieﬂy, 50 mg of cell membranes were incubated in 0.5 ml ice-cold
HEPES buffer (10 mM, pH 7.4) containing 1 nM [3H]granisetron in the presence or
absence of BB (up to 2.5 mM), GB (up to 2.5 mM) or PXN (up to 5 mM); non-speciﬁc
binding was determined using 1 mM quipazine. Reactions were incubated for at
least 1 h at 4 C and terminated by vacuum ﬁltration using a Brandel cell harvesteronto GF/B ﬁlters pre-soaked in 0.3% polyethyleneimine. Radioactivity was deter-
mined by scintillation counting using a Beckman BCLS6500 (Fullerton, California,
USA). Data were analysed by iterative curve ﬁtting (GraphPad Prism v3.02)
according to the equation:
BL ¼ Bmin þ
Bmax  Bmin
1þ 10nHðlog L50log LÞ (5)
where L is the concentration of ligand present; BL is the binding in the presence of
ligand concentration L; Bmin is the binding when L¼ 0; Bmax is the binding when
L¼N, L50 is the concentration of L which gives a binding equal to (Bmaxþ Bmin)/2;
and nH is the Hill coefﬁcient. Results are presented as mean S.E.M.. Statistical
analysis was performed using ANOVA in conjunctionwith a Dunnett’s post-hoc test.
3. Results
3.1. Inhibition of 5-HT3 receptor currents
Oocytes injected with cRNA encoding human 5-HT3A and
5-HT3AB receptors responded to application of 5-HT in a concentra-
tion-dependent manner. Data was ﬁtted with Eq. (1) to yield the
pEC50 and Hill Slope values that are shown in Table 1. These are
similar to previously published results (Thompson and Lummis,
2008). None of the compounds had effects on uninjected oocytes
and none of the compounds elicited a response when applied alone.
BB, GA, GB, PTNand PXN caused concentration-dependent inhibition
of 5-HT EC50 responses thatwas unchanged by pre-application of the
compounds (Fig. 2, Table 2). Upon washout of a very high concen-
tration of BB (6 mM), a transient rebound current was observed
(channel block is relieved and abrief currentﬂowsbefore the channel
closes; Fig. 2A, inset), but none of the other compounds showed this
behaviour across the rangeof concentrations shown. Thepotencies of
the compounds were lower at 5-HT3AB receptors (Fig. 2, Table 2). As
GB and PXN were considerably more potent than GA and PTN, no
further work was performed on the latter compounds.
3.2. Competition binding
At 5-HT3A receptors the pKd of [3H]granisetron was 9.03 0.06
(n¼ 8, Kd¼ 0.93 nM), and at 5-HT3AB receptors was 9.04 0.05
(n¼ 6, Kd¼ 0.91 nM). Binding of [3H]granisetron (1 nM) to human
5-HT3A or 5-HT3AB receptors was not affected by BB (2.5 mM), GB
(2.5 mM) or PXN (5 mM).
PTX-induced inhibition of murine 5-HT3 receptor currents has
been previously reported, but no radioligand binding data was
shown (Das and Dillon, 2003). Here, competition binding with
granisetron (0.5 nM) on the mouse 5-HT3A (pKd¼ 9.30 0.05,
n¼ 11) and 5-HT3AB (pKd¼ 9.26 0.20, n¼ 3) receptors showed
that this ligand was not displaced by high concentrations of BB
(2.5 mM), GB (2.5 mM) or PXN (5 mM).
3.3. Mechanism of action
As the IC50 values of BB, GB and PXN were high at 5-HT3AB
receptors, the mode of action was only studied at 5-HT3A recep-
tors. Application of each of the compounds in the absence of 5-HT
(Fig. 3) did not change the peak response of subsequent 5-HT
applications, suggesting that the compounds can only access the
binding site in the open state. This suggests open channel block,
but examination of inhibition at a ranged of holding potentials
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Fig. 2. BB (panel A), GB (panel B), PXN (panel C) and PTN (panel D) inhibition of the 5-HT3A (ﬁlled squares, solid line) and 5-HT3AB (open squares, dotted line) receptor EC50
responses. A inset shows the current rebound sometimes observed following the removal of high concentrations of BB. Panel E shows current-voltage relationships for 5-HT3A
receptor responses in the presence of BB, GB, PXN or PTN. The curves have been normalised to the current at measured at 90 mV, and the inset shows the ratios of current
amplitudes recorded at þ40 mV relative to those at 40 mV. The ratios in the absence of antagonist were unaltered in the presence of BB, GB, PTN or PXN. GA inhibition is not
shown as only minimal inhibition was seen at 1 mM in the 5-HT3A receptor only.
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dence (Fig. 2D). Use-dependence of BB, GB and PXN was also
examined, and Fig. 3A illustrates the currents induced by 3 mM
5-HT applied at 1 min intervals, in the continued presence of
antagonist. With BB and PXN, the level of inhibition of the 3 mM
5-HT response remained stable during successive applications. In
contrast, the continued presence of 300 mM GB produced
a progressive decrease in the peak current with subsequent 5-HT
applications, indicating that this compound was use-dependent.
When saline rather than GB was perfused between the co-appli-
cations this was not seen, suggesting that the behaviour was
a consequence of the accumulated inhibition. The GB response
only recovered to its pre-treatment amplitude after two agonist
applications, showing that recovery was dependent on channelactivity (Fig. 3A). Across the range of GB concentrations shown in
Fig. 2B, responses did not show increased levels of inhibition with
prolonged applications of the compound, and did not rebound
following its removal.
Concentration-response curves in the presence of increasing
concentrations of PXN (between 1e50 IC50) displayed rightwards
shifts and a reduction in the maximal current (Fig. 4A). The same
effects have been previously observed for non-competitive antag-
onists at 5-HT3 receptors (Thompson et al., 2007), and have
a variety of possible explanations (see discussion). The low potency
of BB and GB meant we had insufﬁcient quantities to perform
experiments across a similar range of compound concentrations. To
overcome this limitation we developed the mathematical model
that is presented below.
Table 2
Parameters obtained from concentration-inhibition curves.
Compound pIC50 (M) IC50 (mM) Hill slope n
5-HT3A
BB 3.33 0.03 470 1.48 0.16 6
GA <3.0 >1000 e 4
GB 3.14 0.05 730 1.10 0.13 4
PTN 3.33 0.05 470 1.33 0.15 6
PXN 4.97 0.12 11 0.68 0.12 13
5-HT3AB
BB 2.50 0.10 3200 0.75 0.13 4
GA <3.0 >1000 e 4
GB 2.41 0.22 3900 0.52 0.14 4
PTN 2.53 0.04 2900 0.99 0.07 4
PXN 4.20 0.11 62 0.68 0.10 5
Values (mean SEM) were derived from concentrationeinhibition curves of wild
type 5-HT3 receptors expressed in Xenopus oocytes. Inhibition was recorded at the
5-HT EC50 concentration at both 5-HT3A (1.7 mM) and 5-HT3AB (28 mM) receptors.
Concentrationeinhibition curves for GA did not converge as inhibition did not
exceed 50% at the highest concentration used (1 mM).
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To probe independence of binding sites at the 5-HT3A receptor,
we compared the levels of inhibition displayed by two compounds
applied separately or together (Table 3). Predicted values for the
level of inhibition expected with both compounds were derived as
described in Material and Methods. For each combination of BB, GB
and PXN, the observed level of inhibition was closest to the pre-
dicted value using Scenario 1 (common binding regions). For BB /GB
and BB /PXN, the observed data was not signiﬁcantly different from
the predicted values using Scenario 1, but was signiﬁcantly
different from those using Scenario 2. These data suggest that these
compounds share at least part of the same binding site. For GB
/PXN, the differences between the observed and predicted levels of
inhibition were not signiﬁcant.
4. Discussion
The ginkgolides are a class of therapeutic agents that can act at
a variety of anion-selective Cys-loop receptors. Here we show that
they can also act at cation selective receptors: BB and GB inhibit
5-HT3A receptor function by blocking the receptor channel,
although they are ∼100 fold less potent than at GABA and glycine
receptors (Huang et al., 2004; Hawthorne et al., 2006), suggesting
that it is not action at this excitatory Cys loop receptor that
contributes to their anxiolytic e or other in vivo e properties.
Nevertheless these compounds are potentially useful pharmaco-
logical tools as they can discriminate between homomeric (5-HT3A)
and heteromeric (5-HT3AB) receptors, a property shared by PTX,
but few other compounds. We also show that PXN, which is
structurally related to the ginkgolides, is the main active compo-
nent of PTX at the 5-HT3A receptor and has a site of action that
overlaps with that of BB.
PTX has previously been shown to inhibit 5-HT3 receptors by
blocking the channel (Das and Dillon, 2003, 2005). As our data
indicated GB and BB do not act at the orthosteric binding site, we
predicted that these compounds would also block the channel, and,
if so, may bind at the same location as PTX. To test this hypothesis
we set up a simple mathematical model to analyse the results of
co-application experiments. The question we were seeking to
address was whether the extent of blockade of an open channel
was the samewhen two compounds acting in the channel compete
for a single site or bind independently to separate sites. In either
case, the binding of one single compound would cause complete
functional blockade. A statistical analysis of the data revealed thatin the 5-HT3A receptor the BB binding site overlaps with that of GB
and PXN (Table 3), supporting our hypothesis that these three
compounds block the 5-HT3A receptor channel by binding in
a similar location. The same analysis was not performed on
5-HT3AB receptors which required much higher concentrations for
inhibition.
Most of the work on ginkgolide action at Cys loop receptors has
been performed on GABA and glycine receptors, where BB, GB and
PTX at low micromolar concentrations have been shown to bind to
and block the receptor channel: In the GABAA receptor, for example,
PTX protects against MTS modiﬁcation of residues at the cyto-
plasmic end of M2, and mutations in this region effect PTX inhi-
bition, but not GABA EC50 or benzodiazepine modulatory effects
(Sedelnikova et al., 2006; Ticku et al., 1978; Xu et al., 1995). In silico
docking into GABAA and glycine receptors shows that ginkgolides
and PTX can dock in the pore, and has provided plausible binding
locations and ligand orientations (Hawthorne and Lynch, 2005;
Erkkila et al., 2008; Hawthorne et al., 2006; Jensen et al., 2008;
Yang et al., 2007). Our data show that the 5-HT3A receptor
channel is also the most likely site of action as BB and GB do not
displace the competitive antagonist [3H]granisetron, the effects of
PXN on 5-HT-evoked currents were insurmountable, and there is
overlap between the BB and PXN, and BB and GB binding sites.
For PXN a reduction in the maximal current and a rightward
shift of the concentrationeresponse curve was seen. True non-
competitive antagonists have a constant IC50 regardless of the
agonist concentration, although some open channel blockers can
cause an apparent increase in afﬁnity as the antagonist effectively
becomes less active at low agonist concentrations, because there
are fewer receptors in the activated state. Apparent decreases in
afﬁnity (i.e. rightwards shifts), however, have been observed for
some channel blockers, and mixed competitive /non-competitive
behaviours or receptor reserve are often used to explain these data
(e.g. Buisson and Bertrand, 1998). Concentration-response curves
could be similarly altered if the antagonist preferentially binds to
a speciﬁc receptor state, or there are different on and off rates of the
agonist /antagonists concerned (see e.g. Smart and Constanti,1986).
Thus our data have various possible explanations, but do not prove
or disprove open channel block. Voltage-dependence is also often
cited as evidence for open channel block, but, as all the compounds
that displayed inhibitory behaviours in this study were uncharged,
it is not surprising that their actions were voltage-independent. To
further probe channel block we examined use dependence. Our
experiments show a weak use-dependence with GB supporting
open channel block, and, although this was not seen for BB and
PXN, recovery from GB inhibition was dependent on channel
activity, which is also characteristic of open channel block. We
conclude that these compounds occupy the open channel, but may
access the binding site slowly and /or preferentially bind to a closed
state.
This study also demonstrates that PXN is the active component
of PTX at 5-HT3 receptors. PTX is a well established channel blocker
at a range of Cys-loop receptors, and at the majority of receptors,
PXN is more potent than PTN, e.g. in the GABAA receptor PXN is ∼50
fold more potent than PTN, and ∼30 fold more potent in glycine a2
receptors (Chen et al., 2006; Curtis and Johnston, 1974; Yang et al.,
2007). However, there are exceptions as PXN and PTN have similar
IC50 values at glycine a1 (∼5 mM) and a1b (∼30 mM) receptors (Yang
et al., 2007). Structurally, PTN is almost identical to PXN (only
differing in hydroxylation of the isoprenyl side chain; Fig. 1), indi-
cating that the protein-receptor interaction at the 5-HT3 receptor
is highly speciﬁc. Similarly, ginkgolides, which have very subtle
chemical differences, can have different relative potencies at
different Cys-loop receptors suggesting they have speciﬁc binding
sites; the differing behaviours we observed at the 5-HT3A
Fig. 3. Evidence for channel block. A: The use-dependency observed for GB was absent for BB and PXN. For GB, the percentage inhibition measure at peak (313.1%) was less than
that measured during the ﬁrst application (38 0.8%). For GB, full recovery was not seen until a second application of GB was applied (inset); at 0.3 mM GB, the ﬁrst 5-HT response
was 912% of the second 5-HT response. BeD: The inhibition observed following the co-application (i) of each compound was not seen if the same compound was pre-applied
before 5-HT (ii and iii). When compounds were pre-applied immediately before 5-HT (iii), no reduction in the 5-HT response was noted. 5-HT¼ 2 mM. BB¼ 1 mM, GB¼ 300 mM,
PXN¼ 30 mM. For each compound, traces are representative of >5 experiments on 2 batches of oocytes.
A.J. Thompson et al. / Neuropharmacology 60 (2011) 488e495 493receptor with GA and GB also indicate a speciﬁc interaction
(Chatterjee et al., 2003; Heads et al., 2008; Huang et al., 2004 Jaracz
et al., 2004).
The current study also demonstrates that BB, GB and PXN have
distinct potencies at 5-HT3A and 5-HT3AB receptors, with IC50
values∼ 6 fold higher at heteromers. This is consistentwith previous
work on PTX that also showed a 6-fold potency difference between
these receptor types (IC50s derived from data in Holbrook et al.,
2009, using nH¼ 1 and plateau¼ 100), and supports our hypoth-
esis that all these compounds have similar sites of action. In another
studyDas andDillon (2005) usingmurine receptors reported an ∼40fold difference in the IC50 values of PTX (5-HT3A, 41 mM; 5-HT3AB,
1.1 mM), and also showed that an M2 residue (60) was a common
determinant of PTX inhibition. Thus, while it is possible that the
difference in potency is due to different behaviours at these two
subtypes, as, for example, has been described for methadone (Deeb
et al., 2009), we speculate that the mechanisms of action of the
structurally-related gingkolide compounds are similar in homo-
meric and heteromeric receptors, and it is the different pore lining
residues that are the cause of the different potencies.
In conclusion, we have shown that BB and GB are inhibitors of
5-HT3 receptors, and that PXN is the active component of PTX. At
Table 3
Determination of shared or discrete binding sites.
Level of inhibition (1 (I/Imax)) Scenario 1 prediction Scenario 2 prediction ANOVA p n
BB GB PXN Combined
0.30 0.06 e 0.48 0.04 0.54 0.03* 0.57 0.04*y 0.63 0.05y 0.049 5
0.13 0.01 0.25 0.01 0.33 0.01* 0.33 0.02* 0.35 0.02y 0.012 4
0.26 0.05 0.35 0.03 0.47 0.04 0.46 0.04 0.50 0.05 0.629 7
BB, GB, PXN and Combined are experimentally derived. The concentrations of BB (16 mM), GB (11 mM) and PXN (5 mM) were sub-IC50 levels chosen for easy comparison.
Scenarios 1 and 2 are the predicted levels of inhibition for scenarios 1 (shared binding site) and 2 (discrete binding sites), as described in Materials and Methods. For each
pairing, ANOVA was performed to determine the signiﬁcance of differences between Combination, Scenario 1 and Scenario 2. When the result of ANOVA was signiﬁcant,
homogeneous subsets are identiﬁed by * and y.
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Fig. 4. Concentrationeresponse curves in the absence and presence of increasing concentrations of BB and PXN. Increasing the concentration of PXN (Panel A), caused a rightward
shift of the concentration-response curves and a change in maximal current that was consistent with non-competitive antagonism. Because of the low potency and poor compound
solubility at high concentrations, it was not possible to perform experiments at higher concentrations and observe shifts for BB (Panel B) or GB (data not shown). Because of these
limitations, inhibition of the 5-HT3 receptor response was recorded at single compound concentrations, both alone and in combination (see Table 3).
A.J. Thompson et al. / Neuropharmacology 60 (2011) 488e4954945-HT3A and 5-HT3AB receptors the ligands have different potencies,
extending the range of compounds that can differentiate between
homo- and heteromeric 5-HT3 receptor types. The data show that
the sites of action for BB, GB and PXN in 5-HT3A receptors are in the
receptor channel, and their sites overlap. Our results are consistent
with the behaviours of these compounds at other Cys-loop recep-
tors, demonstrating that their mechanism of action is broadly
conserved across the family.
Acknowledgements
We would like to thank the Wellcome Trust for funding
(081925; SCRL, AJT) and a travel grant to SCRL from the University
of Sydney. SCRL is aWellcome Trust Senior Research Fellow in Basic
Biomedical Studies. There are no competing interests.
References
Ahlemeyer, B., Krieglstein, J., 2003. Neuroprotective effects of Ginkgo biloba extract.
Cell Mol. Life Sci. 60, 1779e1792.
Buisson, B., Bertrand, D., 1998. Open channel blockers at the human alpha4beta2
nicotinic acetylcholine receptor. Mol. Pharmacol. 53, 555e563.
Chatterjee, S.S., Kondratskaya, E.L., Krishtal, O.A., 2003. Structure-activity studies
with Ginkgo biloba extract constituents as receptor-gated chloride channel
blockers and modulators. Pharmacopsychiatry 36 (Suppl. 1), S68eS77.
Chen, L., Durkin, K.A., Casida, J.E., 2006. Structural model for g-aminobutyric acid
receptor noncompetitive antagonist binding: widely diverse structures ﬁt the
same site. Proc. Natl. Acad. Sci. U.S.A. 103, 5185e5190.
Chen, P., Ozcan, M., Harnly, J., 2007. Chromatographic ﬁngerprint analysis for
evaluation of Ginkgo biloba products. Anal. Bioanal. Chem. 389, 251e261.
Colquhoun, D., 2006. The quantitative analysis of drug-receptor interactions:
a short history. Trends Pharmacol. Sci. 27, 149e157.
Curtis, D.R., Johnston, G.A.R., 1974. Convulsant alkaloids. In: Simpson, L.L., Curtis,
D.R. (Eds.), Neuropoisons, their Pathophysiological Actions, vol. 2, Poisons of
Plant Origin. Plenum Press, New York, 207e248.
Das, P., Dillon, G.H., 2003. The 5-HT3B subunit confers reduced sensitivity to
picrotoxin when co-expressed with the 5-HT3A receptor. Brain Res. Mol. Brain
Res. 119, 207e212.Das, P., Dillon, G.H., 2005. Molecular determinants of picrotoxin inhibition of
5-hydroxytryptamine type 3 receptors. J. Pharmacol. Exp. Ther. 314, 320e328.
Deeb, T.Z., Sharp, D., Hales, T.G., 2009. Direct subunit-dependent multimodal 5-
hydroxytryptamine3 receptor antagonism by methadone. Mol. Pharmacol. 75,
908e917.
Erkkila, B.E., Sedelnikova, A.V., Weiss, D.S., 2008. Stoichiometric pore mutations of
the GABAAR reveal a pattern of hydrogen bonding with picrotoxin. Biophys. J.
94, 4299e4306.
Gaddum, J.H., 1937. The quantitative effects of antagonistic drugs. J. Physiol. 89,
7Pe9P.
Hawthorne, R., Cromer, B.A., Ng, H.L., Parker, M.W., Lynch, J.W., 2006. Molecular
determinants of ginkgolide binding in the glycine receptor pore. J. Neurochem.
98, 395e407.
Hawthorne, R., Lynch, J.W., 2005. A picrotoxin-speciﬁc conformational change in
the glycine receptor M2-M3 loop. J. Biol. Chem. 280, 35836e35843.
Heads, J.A., Hawthorne, R.L., Lynagh, T., Lynch, J.W., 2008. Structure-activity analysis
of ginkgolide binding in the glycine receptor pore. J. Neurochem. 105,
1418e1427.
Holbrook, J.D., Gill, C.H., Zebda, N., et al., 2009. Characterisation of 5-HT3C, 5-HT3D
and 5-HT3E receptor subunits: evolution, distribution and function. J. Neuro-
chem. 108, 384e396.
Huang, S.H., Duke, R.K., Chebib, M., Sasaki, K., Wada, K., Johnston, G.A., 2004.
Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombi-
nant a1b2g2L GABAA receptors. Eur. J. Pharmacol. 494, 131e138.
Jaracz, S., Nakanishi, K., Jensen, A.A., Stromgaard, K., 2004. Ginkgolides and glycine
receptors: a structure-activity relationship study. Chemistry 10, 1507e1518.
Jarboe, C.H., Poerter, L.A., Buckler, R.T., 1968. Structural aspects of picrotoxinin
action. J. Med. Chem. 11, 729e731.
Jensen, A.A., Bergmann, M.L., Sander, T., Balle, T., 2008. Ginkgolide X is a potent
antagonist of anionic Cys-loop receptors with a unique selectivity proﬁle at
glycine receptors. J. Biol. Chem. 285, 10141e10153.
Kenakin, T.P., 1997. Pharmacological Analysis of DrugeReceptor Interaction. Lip-
pincott-Raven, Philidelphia.
Kiewert, C., Kumar, V., Hildmann, O., Rueda, M., Hartmann, J., Naik, R.S., Klein, J.,
2007. Role of GABAergic antagonism in the neuroprotective effects of bilobalide.
Brain Res. 1128, 70e78.
Kondratskaya, E.L., Betz, H., Krishtal, O.A., Laube, B., 2005. The beta subunit
increases the ginkgolide B sensitivity of inhibitory glycine receptors. Neuro-
pharmacology 49, 945e951.
Liman, E.R., Tytgat, J., Hess, P., 1992. Subunit stoichiometry of a mammalian Kþ
channel determined by construction of multimeric cDNAs. Neuron 9, 861e871.
Perry, N.B., Aiyaz, M., Kerr, D.S., Lake, R.J., Leach, M.T., 2001. NOESY on neurotoxins:
NMR and conformational assignments of picrotoxins. Phytochem. Anal. 12,
69e72.
A.J. Thompson et al. / Neuropharmacology 60 (2011) 488e495 495Sasaki, K., Wada, K., Hatta, S., Ohshika, H., Haga, M., 1997. Bilobalide, a constituent of
Ginkgo biloba L., potentiates drug-metabolizing enzyme activities in mice:
possible mechanism for anticonvulsant activity against 4-O-methylpyridoxine-
induced convulsions. Res. Commun. Mol. Pathol. Pharmacol. 96, 45e56.
Sedelnikova, A., Erkkila, B.E., Harris, H., Zakharkin, S.O., Weiss, D.S., 2006. Stoichi-
ometry of a pore mutation that abolishes picrotoxin-mediated antagonism of
the GABAA receptor. J. Physiol. 577, 569e577.
Smart, T.G., Constanti, A., 1986. Studies on the mechanism of action of Picrotoxinin
and other convulsants at the Crustacean muscle GABA receptor. Proc. R. Soc.
Lond. B. Biol. Sci. 227, 191e216.
Thompson, A.J., Lummis, S.C., 2006a. 5-HT3 receptors. Curr. Pharm. Des. 12,
3615e3630.
Thompson, A.J., Lummis, S.C.R., 2006b. The relationship between structure and
function in the 5-HT3 receptor: the transmembrane domain. In: Arias, H.R. (Ed.),
Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor
Superfamilies. Research Signpost, Kerala, India, pp. 155e170.Thompson, A.J., Lochner, M., Lummis, S.C., 2007. The antimalarial drugs quinine,
chloroquine and meﬂoquine are antagonists at 5-HT3 receptors. Br. J. Pharmacol
151, 666e677.
Thompson, A.J., Lummis, S.C., 2008. Antimalarial drugs inhibit human 5-HT3 and
GABAA but not GABAC receptors. Br. J. Pharmacol. 153, 1686e1696.
Ticku, M.K., Ban, M., Olsen, R.W., 1978. Binding of [3H]alpha-dihydropicrotoxinin,
a gamma-aminobutyric acid synaptic antagonist, to rat brain membranes. Mol.
Pharmacol. 14, 391e402.
van Beek, T.A., 2005. Ginkgolides and bilobalide: their physical, chromatographic
and spectroscopic properties. Bioorg. Med. Chem. 13, 5001e5012.
Xu, M., Covey, D.F., Akabas, M.H., 1995. Interaction of picrotoxin with GABAA
receptor channel-lining residues probed in cysteine mutants. Biophys. J. 69,
1858e1867.
Yang, Z., Cromer, B.A., Harvey, R.J., Parker, M.W., Lynch, J.W., 2007. A proposed
structural basis for picrotoxinin and picrotin binding in the glycine receptor
pore. J. Neurochem. 103, 580e589.
